RESUMEN
Broadband optical parametric amplification in the IR region has reached a new milestone through the use of a non-collinear Frequency domain Optical Parametric Amplification system. We report a laser source delivering 11.6 fs pulses with 30 mJ of energy at a central wavelength of 1.8 µm at 10 Hz repetition rate corresponding to a peak power of 2.5 TW. The peak power scaling is accompanied by a pulse shortening of about 20% upon amplification due to the spectral reshaping with higher gain in the spectral wings. This source paves the way for high flux soft X-ray pulses and IR-driven laser wakefield acceleration.
RESUMEN
Long-term outcome of patients with chronic hepatitis B virus (HBV) infection under continuous nucleos(t)ide analogues (NUCs) has been poorly elucidated. We enrolled 121 anti-HBe-positive patients into a prospective surveillance programme while on (>36 months) NUCs therapy. HBV-DNA clearance, add-on therapy and safety were evaluated. Development of cirrhosis, events of liver decompensation and hepatocellular carcinoma (HCC) during the follow-up were the main endpoints, as the complication-free survival. At baseline, 74 patients (61%) had chronic hepatitis, the remainders a cirrhotic liver. HBV-DNA levels >38 000 IU/mL were discovered in 103 patients. At enrolment, 79 patients were naïve to NUCs treatment. Lamivudine monotherapy (n = 70) or a different NUC (n = 51) was administered. At month 6 of therapy, HBV-DNA clearance was documented in 88 patients (73%). Treatment schedule was modified in 52 patients due to breakthrough or suboptimal response. During a mean follow-up of 6 ± 3 years, viral clearance was achieved in the majority of patients. Ten of 74 patients (13.5%) with chronic hepatitis progressed to cirrhosis, 1 patient developed a HCC. In the 47 patients with cirrhosis at presentation, HCC occurred in 14 (30%) and liver decompensation in 5 (11%). The 5 and 10-year event-free survivals were, respectively, 89.3% (95% CI, 81.7 -96.9) and 75.6% (95% CI, 61.5 -89.7) for patients with chronic hepatitis, and 70.2% (95% CI, 56.3 -84.1) and 40.4% (95% CI, 16.9 -63.9) for those with cirrhosis. Protracted, effective treatment with oral NUCs affects the natural history of chronic HBV infection by reducing the incidence of cirrhosis and risk of complications, but does not guarantee against the development of HCC in cirrhosis at presentation.
Asunto(s)
Antivirales/uso terapéutico , Hepatitis B Crónica/tratamiento farmacológico , Nucleósidos/uso terapéutico , Adulto , Anciano , Antivirales/efectos adversos , Carcinoma Hepatocelular/epidemiología , Carcinoma Hepatocelular/prevención & control , ADN Viral/sangre , Femenino , Insuficiencia Hepática/epidemiología , Insuficiencia Hepática/prevención & control , Hepatitis B Crónica/complicaciones , Humanos , Incidencia , Cirrosis Hepática/epidemiología , Cirrosis Hepática/prevención & control , Neoplasias Hepáticas/epidemiología , Neoplasias Hepáticas/prevención & control , Masculino , Persona de Mediana Edad , Nucleósidos/efectos adversos , Análisis de Supervivencia , Resultado del Tratamiento , Carga ViralRESUMEN
Two-color (x-ray+infrared) electron spectroscopy is used for investigating laser-assisted KLL Auger decay following 1s photoionization of atomic Ne with few-femtosecond x-ray pulses from the Linac Coherent Light Source. In an angle-resolved experiment, the overall width of the laser-modified Auger-electron spectrum and its structure change significantly as a function of the emission angle. The spectra are characterized by a strong intensity variation of the sidebands revealing a gross structure. This variation is caused, as predicted by theory, by the interference of electrons emitted at different times within the duration of one optical cycle of the infrared dressing laser, which almost coincides with the lifetime of the Ne 1s vacancy.
RESUMEN
Hepatitis B virus (HBV) infection may run undetected. Unawareness of an ongoing infection delays the diagnosis of HBV-related liver disease and favours the spread of the virus. We have evaluated among hepatitis B surface antigen-positive (HBsAg) inpatients admitted to a Southern Italian hospital the proportion of those aware of their carrier status and correlated the status to signs of liver disease. All patients admitted to the San Giovanni Rotondo Hospital from March 2008 to July 2009 were tested for HBV and hepatitis C virus (HCV) markers, and those positive for HBsAg were interviewed and underwent examinations for liver function and abdominal ultrasound. Overall, of 25,000 patients admitted during the observation period 311 (1.2%) were positive for HBsAg, most of them (98%) being anti-HBe positive. HCV and HDV co-infections were ascertained in 2.9% and 0.6% of cases, respectively. Two hundred and fifty-three subjects (81%) agreed to undergo further investigation, 132 of them (52%) were HBV-DNA positive. One hundred and two patients (40.3%) were unaware of their infection; this was encountered among 29% of HBV-DNA-positive and 52% of HBV-DNA-negative subjects (P < 0.01). Subjects already aware of their infection were more likely to present with abnormal alanine aminotransferase (ALT) levels (27%vs 15%), serological presence of HBV-DNA (63.6% vs. 36%) and liver cirrhosis (30%vs. 13%). A high proportion of HBsAg-positive patients (40.3%) were unaware of their infection, which had evolved to the stage of liver cirrhosis in a consistent percentage of them.
Asunto(s)
Antígenos de Superficie de la Hepatitis B/sangre , Hepatitis B/diagnóstico , Adulto , Anciano , Alanina Transaminasa/sangre , Portador Sano/virología , ADN Viral/sangre , ADN Viral/inmunología , Femenino , Conocimientos, Actitudes y Práctica en Salud , Hepatitis B/sangre , Hepatitis B/patología , Hepatitis B/virología , Anticuerpos contra la Hepatitis B/inmunología , Antígenos de Superficie de la Hepatitis B/inmunología , Virus de la Hepatitis B/genética , Virus de la Hepatitis B/inmunología , Humanos , Pacientes Internos , Italia , Cirrosis Hepática/virología , Masculino , Persona de Mediana EdadRESUMEN
OBJECTIVES: The -A2518G variation in monocyte chemoattractant protein (MCP)-1 gene promoter has been associated with autoimmune diseases. Our aim was to investigate the gene polymorphism and MCP-1 plasma levels in patients with inflammatory bowel disease (IBD). METHODS: Family-based and case-control association analyses of the -A2518G polymorphism (rs1024611) were performed in 1,936 subjects (770 patients with Crohn's disease (CD), 316 patients with ulcerative colitis (UC), 302 healthy relatives (151 CD trios), and 548 healthy controls (HCs)). Extensive gene sequencing was also undertaken, and a further six single-nucleotide polymorphisms (SNPs) were genotyped in 435 CD patients and 189 HCs. MCP-1 protein plasma levels in 234 CD patients, 117 UC patients, and 108 HCs were assessed by an immunosorbent assay. RESULTS: Five SNPs in strong linkage disequilibrium (D'>0.85) were associated with CD, with the strongest signal found at the -A2518G SNP. The frequency of the G allele was significantly lower in CD patients (22.1%), compared with HCs (29.8%), both at case-control (P=6 x 10(-6)) and at transmission disequilibrium test analyses (T/U 41/88; P=4 x 10(-4)). No difference in alleles (26.1%) and genotype frequencies were found in UC patients. MCP-1 plasma levels in CD and UC patients were similar to those in HCs (P=0.38), irrespective of disease activity, or MCP-1 genotypes. However, 30 CD (13%) and 20 UC patients (17%) with extensive colonic involvement had plasma levels significantly higher than HCs (P=0.02). CONCLUSIONS: The -A2518G polymorphism seems to be associated with CD but does not influence MCP-1 plasma levels, which in contrast are increased in UC and CD with extensive colonic involvement.
Asunto(s)
Quimiocina CCL2/genética , Colitis Ulcerosa/genética , Enfermedad de Crohn/genética , Adulto , Alelos , Estudios de Casos y Controles , Quimiocina CCL2/inmunología , Distribución de Chi-Cuadrado , Colitis Ulcerosa/inmunología , Enfermedad de Crohn/inmunología , Ensayo de Inmunoadsorción Enzimática , Femenino , Frecuencia de los Genes , Genotipo , Humanos , Desequilibrio de Ligamiento , Masculino , Fenotipo , Polimorfismo de Nucleótido Simple , Estadísticas no ParamétricasRESUMEN
Following a review of the literature, the relationship between diet and the onset of colorectal cancer is analysed starting from the consideration that in Italy about 20,000 people every year from carcinoma of the colon and 50% of these do not survive. The authors proceed to analyse the epidemiological data which point to diet as an aetiological factor in the cancerogenesis of a variety of tumours in spite of the fact that none of the individual nutritional components has been specifically identified as a triggering and/or protective agent, with the exception perhaps of alcohol in the cancer-cirrhosis sequence. They conclude by stating that, while continuing to give the correct importance to integrated surgical, chemo and radio treatment, to prevent the onset of tumours of the large intestine it is useful to associate the support of a complete nutritional education, which should be begun as soon as possible, with the canonical screening techniques. This educational programme should stress the importance of diet as a contributor of protective principles such as fruit, vegetables, vitamins and non-absorbable fibres which reduce contact time between the carcinogenic substances derived from a prevalently meat diet (cholesterol stimulates the production of biliary salts by increasing the quota of taurodesoxycolic and lithocolic acid and other carcinogenic factors represented by conservants and chemical additives such as nitrates and nitrites which can have a carcinogenetic activity) and the intestinal mucosa.
Asunto(s)
Neoplasias Colorrectales/etiología , Fenómenos Fisiológicos de la Nutrición , Neoplasias Colorrectales/epidemiología , Neoplasias Colorrectales/mortalidad , Neoplasias Colorrectales/prevención & control , Dieta , Fibras de la Dieta/administración & dosificación , Frutas , Educación en Salud , Humanos , Italia/epidemiología , Factores de Riesgo , Verduras , Vitaminas/administración & dosificaciónRESUMEN
AIM OF THE STUDY: to compare AG versus MAC using propofol & remifentanil in a day surgery setting evaluating intra and postoperative clinical conditions and emergence times. METHODS: Propofol and remifentanil, either for general anesthesia (AG) then conscious sedation (MAC), have been administered to 218 patients undergoing mainly plastic or proctologic surgery as day hospital. AG was induced with propofol 1.5-2 mg/kg followed by a continuous infusion of 10 mg/kg/h and remifentanil infused at 10 micrograms/kg/h; MAC was started with propofol 3 mg/kg/h and remifentanil 4-5 micrograms/kg/h; during the maintenance phase of both AG and MAC, infusion rates of both drugs were adjusted according to clinical needs. Diazepam (0.05-0.06 mg/kg) and/or midazolam (2-3 mg) were given as premedication or coinduction as necessary. All patients received field infiltration with local anesthetics (lidocaine or mepivacaine); patients under GA were artificially ventilated with O2/air through IOT or LMA. Surgical and anesthesiological data were collected on specially designed records, with special attention to time intervals between anesthesia (FA) and surgery (FC) end and eyes opening (EO), orientation (OR), return of spontaneous breathing (SR), extubation (EST), sitting (SED), walking (CAMM), dressing (VEST) and discharge (DIM); data were analyzed with parametric and non parametric analysis of variance. RESULTS: All emergence intervals were longer under AG than under MAC: the earlier in the range of 4-5 vs 0.5-1 min; for the late intervals; FA-SED 24 +/- 18 vs 15 +/- 8, FA-PIED 65 +/- 48 vs 34 +/- 17, FA-VEST 69 +/- 58 vs 33 +/- 17, FA-CAMM 68 +/- 42 vs 39 +/- 19. Discharge times (83 +/- 67 vs 73 +/- 60) were similar between the two groups. Drugs consumption under AG were roughly double than under MAC; total dose infused of propofol (mg/kg/min) 0.118 +/- 0.044 vs 0.06 +/- 0.036; total dose of remifentanil (microgram/kg/min): 0.106 +/- 0.049 vs 0.066 +/- 0.027. AG resulted in a higher % incidence of intraoperative hypotension and bradycardia: hypotension 61.7 vs 25.7 and bradycardia 30.3 vs 12.4. SaO2 decreased more commonly during MAC than AG (20.9% vs 10.1); intraoperative itching was referred in 20% of MAC patients. Conversions rate from MAC to AG was 2.8%. Psychomotor agitation was more frequent following AG (14%) than MAC (2%); nausea (1%), vomiting, shivering (12%), headache (2%), ortostatic hypotension (2%) were similar between the two groups. Diazepam and/or midazolam caused a significant prolongation of recovery intervals, for both AG and MAC with a mean delay of the order of 100-200%. CONCLUSIONS: Propofol- remifentanil gave excellent conditions for a wide variety of day surgery procedures, offering good anesthesia with quick emergence; the addition of bdz, even at low doses, prolongs significantly discharge times.
Asunto(s)
Procedimientos Quirúrgicos Ambulatorios , Anestésicos Intravenosos , Piperidinas , Propofol , Adulto , Periodo de Recuperación de la Anestesia , Anestesia General , Sedación Consciente , Diazepam/administración & dosificación , Diazepam/efectos adversos , Humanos , Midazolam/administración & dosificación , Midazolam/efectos adversos , Medicación Preanestésica , RemifentaniloRESUMEN
In order to investigate what is the best single parameter to predict the leukapheretic yield of circulating CD34+ progenitor cells, we retrospectively analyzed data from 68 patients with hematological malignancies who underwent mobilizing therapy. Three main parameters were monitored: total white blood cell (WBC), CD34+ cells, and monocyte counts in peripheral blood (PB) at the same day and at the preceding day of the apheretic procedure. Linear regression analysis revealed a strong correlation between CD34+ cell value in PB just before harvest and the number of CD34+ cells collected (P < 0.0001), but not at the preceding day. Monocyte PB concentration and absolute WBC count did not correlate with CD34+ cells harvested, at the preceding day of leukapheresis as well as at the same day of the procedure. The number of CD34+ cells in mobilized PB at the same day of harvest evidenced a very good capacity of predicting the value of harvested CD34+ cell number after collection, while WBC and monocyte count displayed quite a wide dispersion of results. In particular, an amount greater than 50/microL of circulating CD34+ cells ensured the best collections. Finally, CD34+ and CFU-GM content evaluated for each apheresis showed a strong reciprocal correlation (r 0.78; P < 0.0001). We conclude that the absolute number of CD34+ cells at the day of leukapheresis is the only parameter for identifying the exact timing for apheresis and predicting the amount of peripheral blood progenitor cells (PBPCs) that will be collected. In this setting, WBC and monocyte counts, at the day of collection or at the preceding day, are not useful tools.
Asunto(s)
Antígenos CD34/sangre , Neoplasias Hematológicas/sangre , Movilización de Célula Madre Hematopoyética , Células Madre Hematopoyéticas/inmunología , Adolescente , Adulto , Anciano , Recuento de Células , Niño , Preescolar , Ensayo de Unidades Formadoras de Colonias , Granulocitos/citología , Células Madre Hematopoyéticas/citología , Humanos , Leucaféresis , Recuento de Leucocitos , Modelos Lineales , Macrófagos/citología , Persona de Mediana Edad , Monocitos/citología , Estudios Retrospectivos , Factores de TiempoRESUMEN
We report a case of de novo plasma cell leukemia, resistant to standard VMD (vincristine, mitoxantrone, dexamethasone) and CVP (cyclophosphamide, vincristine and prednisone) protocols, treated with a chemotherapy intensification regimen (high-dose cyclophosphamide, modified EDAP, Dexa-BEAM) and peripheral blood stem cell transplantation, performed using fractionated total body irradiation and high dose melphalan. The patient is currently alive and well, in very good partial remission 12 months after transplant and 22 months after diagnosis, disclosing a significant proportion of bone marrow and peripheral blood CD3+, CD8+, CD57+, HLA-Dr+ large granular lymphocytes with cytotoxic activity against neoplastic plasma cells.
Asunto(s)
Trasplante de Células Madre Hematopoyéticas , Leucemia de Células Plasmáticas/terapia , Recuento de Linfocitos , Subgrupos de Linfocitos T , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carmustina/administración & dosificación , Cisplatino/administración & dosificación , Ciclofosfamida/administración & dosificación , Citarabina/administración & dosificación , Dexametasona/administración & dosificación , Etopósido/administración & dosificación , Humanos , Leucemia de Células Plasmáticas/tratamiento farmacológico , Leucemia de Células Plasmáticas/patología , Masculino , Melfalán/administración & dosificación , Melfalán/uso terapéutico , Mitoxantrona/administración & dosificación , Prednisona/administración & dosificación , Inducción de Remisión , Acondicionamiento Pretrasplante , Vincristina/administración & dosificación , Irradiación Corporal TotalRESUMEN
BACKGROUND: Hematopoietic progenitor cells (HPC), identified by expression of the CD34 surface antigen, show morphological and phenotypic heterogeneity in bone marrow (BM) and peripheral blood (PB). METHODS: CD34+ HPC subpopulations present in 18 PB leukaphereses after high-dose chemotherapy in cancer patients and in 11 BM samples from patients with stage IA lymphoma were characterized. In order to identify CD34+ HPC subsets within these two compartments, the expression of lineage- or activation-associated antigens and the c-kit gene product (CD117) was studied by flow cytometry, using a large panel of monoclonal antibodies (MoAb) in double labelling. RESULTS: We observed a higher proportion of CD34+/CD13+ and CD34+/CD33+ cells (myeloid commitment) in harvested leukapheresis products than in BM. On the contrary, a higher percentage of CD34+/CD10+ and CD34+/CD19+ cells (B-lymphoid commitment) was found in BM. The percentage of the most immature subset of CD34+ HPC (CD38- and HLA-DR-) was also higher in BM than in mobilized PB. No differences in proportions were found with respect to the expression of CD14, CD15, CD45RA (myeloid commitment), CD2, CD5, CD7 (T-lymphoid commitment), CD117, CD71 and CD45RO antigens. In terms of absolute values, however, significantly higher amounts of CD34+ HPC co-expressing CD13, CD33, CD5, CD7, CD71, CD117, CD45RA, CD45RO were detected in leukaphereses than in BM. The absolute number of immature HPC (CD34+/CD38- and CD34+/HLA-Dr-) was also significantly increased in mobilized PB. CONCLUSIONS: Our data confirm the heterogeneous phenotypic profile of HPC, thus supporting the hypothesis that different CD34+ subpopulations may have clinical relevance on the rapidity and long-term durability of engraftment in patients who undergo high-dose chemotherapy followed by rescue with HPC. We also demonstrated that mobilized PB is a particularly rich source of both primitive and committed HPC, more than BM.